RNA therapies that aim for immune stimulation are also under development and mainly focus on anti-cancer treatments such as ASO 1018 ISS targeting TLR-9 for enhancement of cytotoxic effort function in non-Hodgkin’s lymphoma. Here, TLR9 is linked to non-Hodgkin lymphoma.